P-o-c Molecular Diagnostic Market Trends, Analysis, and Forecast till 2034

November 2020
Copyright © PROPHECY MARKET INSIGHTS 2019, All Rights Reserved
Global P-O-C Molecular Diagnostic Market :
Industry, Size, Share, Growth, Trends and
Forecast, 2019–2029

Report Snippet
Copyright © PROPHECY MARKET INSIGHTS 2019, All Rights Reserved 2
Chapter 1 : Table of Contents
Chapter 3: Market Dynamics
Chapter 4: Global P-O-C Molecular Diagnostic
Market , By Product & Solution & Solution
Chapter 2: Market Purview
Market , By Technology
Market , By Region
Chapter 9: Company Profiles Investment Outlook
Future of the Market
Market , By Application
Market , By End User

Table of Contents

Table of Content
Sr. No. Content
1.0 Chapter 1
Research Methodology
Research Objective and Assumption
Research Process
Scope & Coverage
Currency Conversion Rate
2.0 Chapter 2
2.1 Market Purview
2.2 Executive Summary
Market Snippet, By Product & Solution
Market Snippet, By Technology
Market Snippet, By Application
Market Snippet, By End User
Market Snippet, By Region
Opportunity Map Analysis
Market at Glance

Table of Content
Sr. No. Content
3.0 Chapter 3
Drivers
Restrains
Opportunities
Trends
DR Impact Analysis
Porter’s Five Forces Analysis
COVID-19 Impact on the Market
Key Highlights
4.0 Chapter 4
4.0.1 Global P-O-C Molecular Diagnostic Market Value (US$ Bn), By Product & Solution
Segment Overview
Market Value and Forecast (US$ Bn), and Share (%) Analysis, 2018 – 2029
Y-o-Y Growth (%) Analysis, 2019 – 2029
4.1 Kits & Assay
Overview

Table of Content
Sr. No. Content
Market Value and Forecast (US$ Bn), and Y-o-Y Growth (%) Analysis, 2018 – 2029
4.2 Software & Services
Overview
5.0 Chapter 5
5.0.1 Global P-O-C Molecular Diagnostic Market Value (US$ Bn), By Technology
Segment Overview
5.1 PCR-based
Overview
5.2 Genetic Sequencing-based
Overview
5.3 Hybridization-based

Table of Content
Sr. No. Content
Overview
5.4 Microarray-based
Overview
6.0 Chapter 6
6.0.1 Global P-O-C Molecular Diagnostic Market Value (US$ Bn), By Application
Segment Overview
6.1 Respiratory Disease
Overview
6.2 Sexually Transmitted Diseases (STDs)
Overview

Table of Content
Sr. No. Content
6.4 Hospital Acquired Infections (HAIs)
Overview
6.5 Cancer/Oncology
Overview
6.6 Prenatal/Neonatal Testing
Overview
6.7 Other Application
Overview
7.0 Chapter 7
7.0.1 Global P-O-C Molecular Diagnostic Market Value (US$ Bn), By End User
Overview

Table of Content
Sr. No. Content
7.1 Clinics and Diagnostic Laboratories
Overview
7.2 Hospital Outpatient Departments and Intensive Care Units (ICUs)
Overview
7.3 Research and Academic Institutes
Overview
7.4 Other End Users
Overview
8.0 Chapter 7
8.0.1 Global P-O-C Molecular Diagnostic Market Value (US$ Bn), By Region
Overview

Table of Content
Sr. No. Content
8.1 North America
Overview
Market Value and Forecast (US$ Bn), 2018 – 2029
North America P-O-C Molecular Diagnostic Market , By Product & Solution
North America P-O-C Molecular Diagnostic Market , By Technology
North America P-O-C Molecular Diagnostic Market , By Application
North America P-O-C Molecular Diagnostic Market , By End User
North America P-O-C Molecular Diagnostic Market , By Country
U.S.
Canada
8.2 Europe
Overview

Table of Content
Sr. No. Content
Europe P-O-C Molecular Diagnostic Market , By Product & Solution
Europe P-O-C Molecular Diagnostic Market , By Technology
Europe P-O-C Molecular Diagnostic Market , By Application
Europe P-O-C Molecular Diagnostic Market , By End User
Europe P-O-C Molecular Diagnostic Market , By Country
Germany
UK
France
Russia
Italy

Table of Content
Sr. No. Content
Rest of Europe
8.3 Asia Pacific
Overview
Asia Pacific P-O-C Molecular Diagnostic Market , By Product & Solution
Asia Pacific P-O-C Molecular Diagnostic Market , By Technology
Asia Pacific P-O-C Molecular Diagnostic Market , By Application
Asia Pacific P-O-C Molecular Diagnostic Market , By End User
Asia Pacific P-O-C Molecular Diagnostic Market , By Country
India
China
Japan

Table of Content
Sr. No. Content
South Korea
Rest of Asia-Pacific
8.4 Latin America
Overview
Latin America P-O-C Molecular Diagnostic Market , By Product & Solution
Latin America P-O-C Molecular Diagnostic Market , By Technology
Latin America P-O-C Molecular Diagnostic Market , By Application
Latin America P-O-C Molecular Diagnostic Market , By End User
Latin America P-O-C Molecular Diagnostic Market , By Country
Brazil
Mexico

Table of Content
Sr. No. Content
Rest of Latin America
8.5 Middle East & Africa
Overview
Middle East & Africa P-O-C Molecular Diagnostic Market , By Product & Solution
Middle East & Africa P-O-C Molecular Diagnostic Market , By Technology
Middle East & Africa P-O-C Molecular Diagnostic Market , By Application
Middle East & Africa P-O-C Molecular Diagnostic Market , By End User
Middle East & Africa P-O-C Molecular Diagnostic Market , By Country
GCC
Israel
South Africa

Table of Content
Sr. No. Content
Rest of Middle East & Africa
9.0 Chapter 9
9.0.1 Company Profiles
9.1 Abbott Laboratories
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.2 Bayer Healthcare
Company Overview
Product Portfolio
Key Highlights
Financial Overview

Table of Content
Sr. No. Content
Business Strategies
SWOT Analysis
9.3 Cepheid, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.4 Becton, Dickinson and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis

Table of Content
Sr. No. Content
9.5 BioMerieux
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.6 F. Hoffmann-La Roche AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.7 Bio-Rad Laboratories, Inc.
Company Overview

Table of Content
Sr. No. Content
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.8 Danaher Corporation
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.9 Johnson and Johnson
Company Overview
Product Portfolio
Key Highlights

Table of Content
Sr. No. Content
Financial Overview
Business Strategies
SWOT Analysis
9.10 Dako
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
10.0 Chapter 10
Investment Outlook
11.0 Chapter 11
Appendix
Abbreviation

About Us
20

About Us
21
Who we are:
Prophecy is a specialized market research, analytics, marketing
and business strategy, and service offerings company that offer
strategic and tactical support to clients for making well-informed
business decisions and to identify and achieve high value
opportunities in the target business area. Also, we help our client
to address business challenges and provide best possible Service
Offerings to overcome them and transform their business.
Prophecy’s expertize area covers types, applications, latest
trends, developments, market growth factors, and challenges
along with market forecast in various business areas such as
Healthcare, Pharmaceutical, Biotechnology, Information
Technology (IT), Hospitals, Small and Ownership Model-sized
enterprises (SMEs), Chemical, Agriculture, Food and Beverage,
Energy, and Oil and Gas. We also offer various other Adaptive
Pants such as, data mining, information management, and
revenue enhancement suggestions.
Source: Prophecy Market Insights
We are a team of dedicated and impassioned individuals,
who believe strongly in giving our very best to what we do
and we never return down from any challenge. At prophecy
we cater to industries, individuals, and organizations across
the globe and deliver our offerings in the shortest possible
turnaround time.
Our well defined approach ensures our clients will receive
unique competitive advantage, and secure and long lasting
results.
“WE BELIEVE IN LONG–TERM BUSINESS
RELATIONS FOR GROWTH AND SUCCESS”

A rich repository of syndicated
reports across 8 Industries
Dedicated Analyst
Working
More than 100+ Clients
worldwide including various
Fortune 500 Companies
Pioneer in adopting best
research practices to ensure
deeper insights
Top leadership having more
than
50 man years of experience
across varied industries
2+ years of industry
experience in delivering
valuable research Insights at
Global, Regional and Country
Level
About Us

Collection
of
Data
Collaboration
of Data
Identification
of data
Evaluation of
Market
Dynamics
Verification
and Analysis
2.This process consists
of gathering data,
accessing proprietary
databases, and reaching
out to key industry
participants that
operate in the market
across the value chain.
It also involves studying
several patterns in
the historical data and
comparing it with the
current scenario.
4. This is the final stage,
which involves both
quantity and quality
checks. Although the
process of data
verification is an integral
part of the research
process, all data points
and statistics and figures
are re-checked to uphold
their authenticity and
validity.
3.This stage involves the
validation of data and
arrival at actual statistics,
and evolution of the
market over the years. It
entails the study and
analyzes various segments
and Applications of the
market. An impact analysis
is also performed to
observe which factors will
affect the market in the
next few years.
1. This step involves identification of several primary
and secondary data research sources, including
Prophecy internal data sources.
The primary sources consist of in-depth discussions
and interviews with policy makers, industry experts,
and data evaluators, whereas secondary sources
include a thorough study of market journals, press
releases, annual reports, and Others and non Others
agencies websites.
This phase includes a detailed evaluation of several
factors that are likely to affect the market dynamics.
It involves a comprehensive assessment of major
market pain points, drivers, and trends.

Research Objective
To predict the
size of the
market
To offer wide ranging market
statistics with a detailed
classification along with the
market size of each segment
To analyze key
strengths,
opportunities,
and strategies of
major
companies
To outline and forecast the
Governance, Risk Management and
Compliance (GRC) market in globally
based on segmentation and region
To study market
opportunities for
participants and
stakeholders by
identifying high
growth sectors in
the market
To provide comprehensive
information about factors that affect
market dynamics
To analyze several micro-market
indicators considering growth
factors, market prospects, and
strategic market contribution
To examine competitive scenarios
such as collaborations, mergers and
acquisitions, R&D activities, and
advanced developments

Research Process
PROJECT
SCOPE
PROJECT
KICKOFF
PRELIMINARY
RESEARCH
MARKET
ANALYSIS &
SEGMENTATION
REPORT
SYNTHESIS
REPORT
DELIVERY
POST-SALE
SERVICE

Global Market Size
Market/Revenue share of each key player in each
Type segment
Market/Revenue share of each key player in the
global market
Bottom-up Approach –
Collection of market related data and information
from primary and secondary sources, and data
analysis.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources
Market/Revenue share split by each market segment
such as By Product & Solution Fracturing
Fluids/Fracturing Fluids sector/end user
Market/Revenue share split by each region and
country in the global market
Top-down Approach –
Market size and analysis validation through primary
and secondary research participants and key opinion
leaders.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources

Definition and Scope – Prophecy Market Insights provide the market definition to
understand the target Type/service and provide the market scope to understand
the report coverage after thoroughly understanding of target market and market
specific requirements.
Primary Research – We formulates a detailed discussion guide to perform primary
research. In primary research collection of data is performed through telephonic
interview, E-mail questionnaire’s, and in-depth discussion with industry experts,
manufacturers, suppliers, and distributors. The primary research participant
includes but not limited to CEO’s, Managers, Directors, VP’s, Suppliers, CSO’s, and
etc.
Secondary Research – Our research analyst performs in-depth secondary research
and extensive data mining to collect market related information through various
authentic data sources such as Annual Reports, Trade Publications, G6, Research
Publications, Company Press Release, and some paid data sources.
In-house Data Analysis – After extensive data mining, we perform in-house market
analysis by using various data tools, statistical methods, and data analysis tools to
arrive on a conclusion and reduce the margin of error. We provide our overviews
and market forecast for the target market after thoroughly understanding and
analyzing of collected data, historic market trends, and research outputs.
Report Delivery – Prophecy Market Insights provide report in required electronic
format (preferably in PDF format), as PDF format is easy to read and present.

Preface

Scope & Coverage
2019 2020 2021-2029
Base Year Estimated Year Forecast Years
The report considers 2019 as the base year. All calculations involving quantitative data are
based on 2019. The values represented in the report are actual values for 2019, whereas,
the values are estimated for the period 2020−2029.

Market Segmentation
Global P-O-C Molecular Diagnostic Market
By Product & Solution
By Region
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East &
Africa
 Kits & Assays
 Analyzers
 Software &
Services  Respiratory Diseases
 Sexually Transmitted
Diseases (STDs)
 Hospital Acquired
Infections (HAIs)
 Cancer/Oncology
 Prenatal/Neonatal
Testing
 Other Applications
By Application
By Technology
 PCR-based
 Genetic Sequencing-
based
 Hybridization-based
 Microarray-based
By End User
 Clinics and Diagnostic
Laboratories
 Hospital Outpatient
Departments and
Intensive Care Units
(ICUs)
 Research and Academic
Institutes
 Other End Users

Currency Conversion
Currency Conversion 2013-2018
The standard currency used throughout the report is USD ($). However, in the case of other currencies, the annual average currency rate
(January 1 to December 31) is used for conversion. These conversion rates are rounded to the nearest decimal place. The chart below
represents the standard conversion rates used in the report.
Currency Conversion 2013 2014 2015 2016 2017 2018
$/€ USD/EUR 0.7532 0.7535 0.8969 0.8988 0.8605 0.8566
$/£ USD/GBP 0.6395 0.6072 0.6526 0.7309 0.7607 0.7586
$/¥ USD/JPY 98.58 105.84 120.9 107.5269 113.8867 111.0019
$/₭ USD/SEK 6.5127 6.8587 8.404 8.9328 8.4135 8.8826
$/A$ USD/AUD 1.0362 1.1094 1.3112 1.343 1.3042 1.3578
$/¥ USD/RMB (CNY) 6.1905 6.1432 6.1606 6.61 6.6294 6.6675

Market Purview
Chapter 02
3
2

Executive Summary (1/9)
33
Overview
 Molecular diagnostics is broadly used to diagnose and monitor various diseases, detect risks, and to identify beneficial treatment for
patients. In simple terms, molecular diagnostics is a process to identify a disease by studying molecules, such as DNA, RNA, and
proteins, in a tissue or fluid.
 For many years, molecular diagnostics has been conducted in centralized laboratories. However, it has few drawbacks like the high cost
of tests, delay in results, late disease diagnosis, and less accuracy are resulting in to an increase in mortality rate.
 Thus, limiting the growth of this market. Therefore, to overwhelm this, the new technique called a point of care molecular diagnostics
has emerged. This technique has the ability to provide accurate and rapid results in less than 1-2 hours has helped to surge its
adoption in various low-resource settings.
 The global p-o-c molecular diagnostic market accounted for US$ 1.7 billion in 2019 and is estimated to be US$ 6.7 billion by 2029
and is anticipated to register a CAGR of 14.8%.

34
Table 2.1: Global P-O-C Molecular Diagnostic Market Overview
Parameters 2019 (E) 2029 (F)
Global P-O-C Molecular Diagnostic Market Value (US$ Bn) 1.7 6.7| CAGR: 14.8% |
By Product & Solution Segment with Largest Value (US$ Bn) XX XX
By Product & Solution Segment with Highest CAGR (%)-
2019-2029
CAGR- XX%
By Technology Segment with Largest Value (US$ Bn) PCR-based XX PCR-based XX
By Technology Segment with Highest CAGR (%)-2019-2029 xx: CAGR-XX%
To be Continued …

35
Table 2.2: Global P-O-C Molecular Diagnostic Market Overview
Parameters 2019 (E) 2029 (F)
By Application Segment with Largest Value (US$ Bn) XX XX
By Application Segment with Highest CAGR (%)-2019-2029 CAGR: XX
By Region with Largest Value (US$ Bn) North America : XX North America xx
By Region with Highest CAGR (%)-2019-2029 Asia-Pacific: CAGR- XX%
Key Market Players: Abbott Laboratories, Bayer Healthcare, Cepheid, Inc.., Becton,
Dickinson and Company, BioMerieux, F. Hoffmann-La Roche AG, Bio-
Rad Laboratories, Inc., Danaher Corporation, Johnson and Johnson,
and Dako.

36
Description
Figure 2.1: Global P-O-C Molecular Diagnostic Market Value Share (%), By
Product & Solution – 2020 (E)
Analysis
Kits & Assays
Analyzers
Software & Services
 The global p-o-c molecular diagnostic market accounted for US$ 1.7
billion in 2019 and is estimated to be US$ 6.7 billion by 2029 and is
anticipated to register a CAGR of 14.8%.
 Increased need for accurate and faster testing methods and results
for the molecular tests is expected to propel the market growth.
 Kits & Assays are essential components during any laboratory
procedure. Its frequent use in the molecular diagnostic testing
resulted into its higher volume and value share. Apart from this,
growing prevalence of chronic diseases resulted into
technological advancements by the key market players to
expand their product portfolio of disease specific assays for
early diagnosis. In addition, growing focus of key market players
on receiving CLIA approval further support the fastest growth of
kits & assays segment.

PCR-based
Genetic Sequencing-
based
Hybridization-based
Microarray-based
Figure 2.2: Global Portable
Analysis and Outcome
Technology – 2020 (E)
Region – 2019 (E
Application 2020(E)
 Based on technology, the PoC molecular diagnostics market has been categorized into PCR-based, genetic sequencing-based,
hybridization-based, and microarray-based tests and devices. PCR-based tests accounted for the largest revenue share in 2018.
 Commercialization of PoC tests that provide rapid real time PCR analysis with a high level of accuracy for infectious diseases, such as
H1N1 and influenza, will drive the market. NGS-based molecular testing near the patient is anticipated to witness considerable growth
over the forecast period due to a number of developments in the market.
 The respiratory diseases segment dominated the POC molecular diagnostics market in 2019. The factors such as increasing number of
respiratory & associated infectious diseases, large number of commercialized POC molecular diagnostic products for respiratory disease
diagnosis, and focus of key market players on adopting various strategies for commercializing or developing advanced POC molecular
diagnostic products contribute to the largest share of this application segment.
Respiratory Diseases
Sexually Transmitted
Diseases (STDs)
Hospital Acquired
Infections (HAIs)
Cancer/Oncology
Prenatal/Neonatal Testing
Other Applications

Clinics and Diagnostic
Laboratories
Hospital Outpatient
Departments and Intensive
Care Units (ICUs)
Research and Academic
Institutes
Other End Users
Figure 2.2: Global Portable
End User – 2020 (E)
Region – 2019 (E
Region 2020(E)
 At regional level, the overall POC molecular diagnostics market is dominated by North America in 2019, while, Asia Pacific region is
expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of Asia Pacific POC molecular
diagnostics market are rising incidences of chronic diseases associated with geriatric population, expansion of key market players in
this region, insufficient sophisticated central laboratory testing services, and potential cost effectiveness of POC molecular diagnosis.
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

14.8%
Market at Glance
2019
2029
CAGR 2019-2028
US$ 6.7 Bn
US$ 1.7 Bn

Executive Summary
Market at Glance (2020)
North America:
XX Mn
CAGR: XX%
Latin America:
XX Mn
CAGR: XX%
APAC:
XX Mn
CAGR: XX%
Europe:
XX Mn
CAGR: XX%
MEMA:
XX Mn
CAGR: XX%

Market Dynamics
Chapter 03

Drivers (1/6)
Introduction of CLIA waived tests
 The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certified by
the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can
obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.
 Three federal agencies are responsible for CLIA: The Food and Drug Administration (FDA), Center for Medicaid Services (CMS), and the
Centers for Disease Control and Prevention (CDC). Each agency has a unique role in assuring quality laboratory testing.
POCT: Waived versus non-waived
 For differentiation, POCT may be waived or non-waived. Waived testing may be performed at the POC or in a centralized facility. Non-
waived testing is subcategorized as moderately complex and highly complex. The majority of non-waived POCT is moderately complex.
The facility must be diligent regarding adherence to the manufacturer's operating/testing instructions. Regardless of CLIA classification,
methods operated outside of manufacturer's recommendations become highly complex and must function under those federal, state,
and applicable accreditation regulations and guidelines. POCT that is non-waived must follow all regulations for non-waived testing
and have the appropriate CLIA certificate for compliance.

Drivers (2/6)
Growth in business operations by emerging and small sized players
 The state of testing for the novel coronavirus currently spreading globally in the U.S. is abysmal, relative to other developed countries,
but there are a number of efforts underway to help improve availability.

Drivers (3/6)
Rise in funding from government & private institutions
 The NIBIB-funded C enter for Innovation in Point-of-Care technologies for HIV/ AIDS at Northwestern University (C-THAN) seeks
collaborative research projects to develop novel point-of-care technologies (POCT) aimed at improving diagnosis and treatment
monitoring of HIV/AIDS and co-morbidities in low- and middle-income countries (LMIC). If successful, projects should be viable
candidates for commercial development. Awards will be up to $50,000- $100,000 for 12 months.

Drivers (4/6)
Increasing R&D initiatives
 While the world is slowing down because of the coronavirus pandemic, the R&D community is working at full capacity to address the
challenges associated with COVID-19. It is important now, more than ever, for researchers and scientists to unite in this mission. As
CoV-2 is a new virus, each new piece of information could lead to a significant progress in the search for diagnostics or therapeutic
solutions.

Drivers (5/6)
Growing demand for home healthcare and introduction of novel products
 Government and health care officials of various countries plead for expanded access to high-speed COVID-19 tests, and health care
companies across the country began mobilizing their resources to meet the growing demands with direct-to-consumer kits.

Drivers (6/6)
Growing prevalence of target diseases

Restraint (1/3)
High procedure costs

Restraint (2/3)
Technical and clinical-related challenges
 RT-PCR assays are generally considered the gold standard for viral testing. PCR is highly sensitive and detects even a tiny amount of
virus in a patient sample by amplifying regions of genetic code that are specific to the virus. Several global labs took RT-PCR testing and
ran with it. Labs in South Korea, for example, quickly created and deployed thousands of these tests.
 As of late March, several companies had received the EUA for their SARS-CoV-2 tests from the FDA. The majority are the RT-PCR
methods, similar to the WHO’s, that need to be run in CLIA-certified labs with special machinery, reagents, and trained staff. Once in
the lab, they generally take about 3-4 hours to run on the analyzer. However, it may take upwards of 3-7 days to provide results back to
clinicians if you take into account how the sample must be collected at a healthcare provider, shipped to the lab, prepped, analyzed,
reviewed, and then finally reported, generally as a qualitative result (positive or negative).
 While it’s relieving to see how private companies and labs have been able to develop and distribute accurate tests so quickly, even 3
days for a result is a long time during a rapidly spreading pandemic.
 Hospital and health systems using courier services to transport patients’ biological specimens from doctors’ offices and other locations
to clinical laboratories for testing and reporting are finding those services delayed or disrupted by the COVID-19 pandemic.

Restraint (3/3)
Ambiguous regulatory framework

Drivers and Restraints Impact Analysis
Low High
Low
High
Impact on Market Value
Likely
Growth
Impact
on
Market
Growth
Rate
D1
Drivers
Restraints
High procedure costs
R1
D2 Growth in business operations by
emerging and small sized players
Introduction of CLIA waived tests
D3
Rise in funding from government &
private institutions
D4 Increasing R&D initiatives
D5
Growing demand for home
healthcare and introduction of novel
products
D6
Growing prevalence of target
diseases
Technical and clinical-related
challenges
R2
Ambiguous regulatory framework
R3

Opportunity
Increase investment and facility for the research and diagnosis

PORTER’S FIVE FORCES ANALYSIS
Analysis
 The Porter’s five forces model studies the five identified
competitive forces that shape every industry and market, in
order to determine the intensity of the competition, and
thus, the profitability and attractiveness of the industry.
 The objective of the growth strategy is to adapt to these
competitive forces in a manner that may improve the
position of the organization. This study includes an
exhaustive Porter’s five forces framework, incorporating
the factors influencing each force, to analyze the market
from a microeconomic perspective.
 In the study, Porter’s five forces are analyzed considering
the factors influencing each force and quantifying the
factors, through primaries and quantitative analysis. The
quantified factors are further mapped out, to derive the
impact of each force on competitive dynamics.
Outcome
COMPETITIVE
RIVALRY
High

PORTER’S Five Forces Analysis
05
Threat of New
Entrants
Medium
01
02
03
Threats of
Substitutes
High
04
Buyer Power
High
Supplier Power
High
Competitive Rivalry
High

Key Highlights
02 03 04
01

Global P-O-C Molecular Diagnostic Market ,
By Product & Solution
Chapter 04

Table 4.1: Global P-O-C Molecular Diagnostic Market Value and Forecast (US$ Bn), By Product & Solution - 2019–
2029
Global P-O-C Molecular Diagnostic Market, By Product & Solution
Product 2019 H 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
Kits & Assays XX XX XX XX XX XX XX XX XX XX XX XX
Analyzers XX XX XX XX XX XX XX XX XX XX XX XX
Software & Services XX XX XX XX XX XX XX XX XX XX XX XX
Total XX XX XX XX XX XX XX XX XX XX xx Xx

Global P-O-C Molecular Diagnostic Market , By Product & Solution
Figure 4.1 : Global P-O-C Molecular Diagnostic Market Value and Forecast
(US$ Bn), and Y-o-Y Growth (%), By Product & Solution - 2018-2029
 The Global P-O-C Molecular Diagnostic Market was valued by
US$xxBn in 2019 and is expected to reach US$xxBn in 2029,
and register a CAGR of xx% over the forecast period
 The first five year (2019-2023) cumulative value is projected to
be US$XXBn, as compared to relatively higher cumulative
value of US$XXBn for the last five year (2024-2028) of the
forecast period.
XXx: Projected growth between 2019 and 2029
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Kits & Assays

Kits & Assays
Figure 4.2: Global P-O-C Molecular Diagnostic Market Value and Forecast (US$ Bn), and Y-o-Y
Growth (%), By Kits & Assays 2018-2029 Analysis and Outcome
Xx: Projected growth between 2019 and 2029
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Analyzers

Analyzers
Growth (%), By Analyzers 2018-2029 Analysis and Outcome
2.1.x: Projected growth between 2019 and 2029
 The Global P-O-C Molecular Diagnostic Market by Analyzer
was valued US$xxBn in 2019 and is expected to reach US$xxBn
in 2029, and register a CAGR of xx% over the forecast period
be US$xxBn, as compared to relatively higher cumulative value
of US$xxBn for the last five year (2024-2028) of the forecast
period.
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Software & Services

Software & Services
Growth (%), By Software & Services 2018-2029 Analysis and Outcome
2.1.x: Projected growth between 2019 and 2029
 The Global P-O-C Molecular Diagnostic Market by Software &
Services was valued US$xxBn in 2019 and is expected to reach
US$xxBn in 2029, and register a CAGR of xx% over the forecast
period
be US$xxBn, as compared to relatively higher cumulative value
of US$xxBn for the last five year (2024-2028) of the forecast
period.
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Global P-O-C Molecular Diagnostic Market, By
Region
Chapter 08

P-O-C Molecular Diagnostic Market , By Region
Market Share at Glance (2020)
North America:
XX%
Latin America:
XX%
APAC:
XX%
Europe:
XX%
MEMA:
XX%

North America
Market Share (%) - 2020
North America
RoW

xxx
North America

North America
Figure 8.1: North America Market Value and Forecast (US$ Bn), and
Y-o-Y Growth (%), 2019-2028
 The North America was valued at US$ XX Mn in 2019 and
is expected to reach US$ XX Mn in 2029, and register a
CAGR of XX% over the forecast period.
xxX: Projected growth between 2020 and 2029
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

North America P-O-C Molecular Diagnostic Market
U.S.

North America P-O-C Molecular Diagnostic Market
Canada

Table 8.1: North America P-O-C Molecular Diagnostic Market Value and Forecast (US$ Bn), By Product & Solution -
2019–2029
North America P-O-C Molecular Diagnostic Market, By Product &
Solution
Product 2019 H 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
Kits & Assays XX XX XX XX XX XX XX XX XX XX XX XX
Analyzers XX XX XX XX XX XX XX XX XX XX XX XX
Software & Services XX XX XX XX XX XX XX XX XX XX XX XX
Total XX XX XX XX XX XX XX XX XX XX xx Xx

Table 8.2: North America Market Value and Forecast (US$ Bn), By Technology, 2019 – 2029
North America P-O-C Molecular Diagnostic Market, By Technology
Technology 2019 E 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2019–
28)
PCR-based XX XX XX XX XX XX XX XX XX XX XX XX
Genetic Sequencing-
based
XX XX XX XX XX XX XX XX XX XX XX XX
Hybridization-based XX XX XX XX XX XX XX XX XX XX XX XX
Microarray-based XX XX XX XX XX XX XX XX XX XX XX XX
Total XX XX XX XX XX XX XX XX XX XX XX XX

Table 8.3: North America Market Value and Forecast (US$ Bn), By Application, 2019 – 2029
North America P-O-C Molecular Diagnostic Market, By Application
Application 2019 E 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2019–
28)
Respiratory Diseases XX XX XX XX XX XX XX XX XX XX XX XX
Sexually Transmitted
Diseases (STDs)
Hospital Acquired
Infections (HAIs)
Cancer/Oncology XX XX XX XX XX XX XX XX XX XX XX XX
Prenatal/Neonatal
Testing
Other Applications XX XX XX XX XX XX XX XX XX XX XX XX

Table 8.4: North America Market Value and Forecast (US$ Bn), By End User, 2019 – 2029
North America P-O-C Molecular Diagnostic Market, By End User
End User 2019 E 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2019–
28)
Clinics and Diagnostic
Laboratories
Hospital Outpatient
Departments and
Intensive Care Units
(ICUs)
Research and
Academic Institutes
Other End Users XX XX XX XX XX XX XX XX XX XX XX XX

North America P-O-C Molecular Diagnostic Market , By Country
Table 8.5: North America Market Value and Forecast (US$ Bn) By Country, 2019-2029
US Canada
Figure 8.2: North America Market Value (US$ Bn) Overview, By Country 2019 and 2029
Country 2019 E 2020 E 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2019–
28)
U.S. XX XX XX XX XX XX XX XX XX XX XX XX
Canada XX XX XX XX XX XX XX XX XX XX XX XX

Company Profiles
Chapter 09

Becton, Dickinson and Company
Company Overview Business Overview
Product Portfolio
Established 1897
Key Management Thomas Polen (CEO)
Private/Public Public
Headquarter New Jersey, U.S.
Headcount 70,093 (2019)
Geographic Presence
North America, Europe, Asia
Pacific, Latin America, Middle East
& Africa
Total Value (US$ Mn) 17,290 (2019)
Value Growth (%) Over Previous
Year
0.07
Key Usages
Medical Devices, Biosciences,
Medical Supplies, Laboratory
Instruments, Reagents,
Diagnostics Products, Antibodies,
Surgical, and Vascular Access
Website www.bd.com
Source: Company Annual Reports and Website
Becton, Dickinson and Company is a global medical technology
company engaged principally in the development, manufacture,
and sale of medical devices, instrument systems, and reagents
used by healthcare institutions, life science researchers, clinical
laboratories, the pharmaceutical industry, and the general
public.

Key Highlights

Company Financial (US$ Mn) Overview, by Year Analysis and Outcome
12,483 12,093
15,983
17,290
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
2016 2017 2018 2019
 Becton, Dickinson and Company has reported value US$
17,290 Mn, in the year of 2019; which has increased by
0.07% over value of year 2018 which was US$ 15,983 Mn
 Becton, Dickinson & Company is a global medical
technology company that is advancing the world of health
by improving medical discovery, diagnostics and the
delivery of care.
 BD leads in patient and health care worker safety and the
technologies that enable medical research and clinical
laboratories.
 The revenue of 2019 was increased due to the innovative
solutions provided by the company that helps to advance
medical research and genomics, enhance the diagnosis of
infectious disease and cancer, improve medication
management, promote infection prevention, equip surgical
and interventional procedures, and support the
management of diabetes.

67.0%
33.0% BD Medical
BD Life Sciences
Revenue by Segmentation (2018)
Revenue by Product (2019)
10.0%
21.0%
15.0%
54%
U.S
Europe
Asia-Pacific
ROW
Revenue by Regions (2018)
 The majority of the revenue and profit growth of the company was generated from the United States and European countries. The
company is continuously investing in R&D, geographical expansion, and new product promotions.
 In the United States, the economic environment of the healthcare industry is generally stabilized. In emerging markets, the company’s
growth is primarily driven by, and dependent upon, government funding for healthcare systems. In addition, each geographical region
offers challenges related to pricing pressure.

Business Strategies Overview

SWOT Analysis
Becton, Dickinson
and Company
S W
O T
Strengths
Opportunities
Weakness
Threats
 Diversified portfolio of healthcare products.
This ensures well-balanced revenue flow
 Steady revenue growth
 Leading market position
 Product recalls are expected to hamper the
company's brand value, particularly in the
catheter business
 Pacemaker devices can be easily hacked
 Decline in operational performance
 Diversified portfolio, primarily through
acquisition and integration of firms, as part of
its inorganic growth strategy
 Strong business partnerships
 The company’s products, R&D activities, and
manufacturing processes are subject to various
local, state, federal, foreign, and transnational
laws and regulations.
 Patent expirations are expected to impact the
company's gross revenue.

Future Opportunity

Additional growth opportunities participants should aim to secure include:

About Us
Copyright © PROPHECY 2019, All Rights Reserved 87
Disclaimer
 The material is based on sources which we believe are reliable, but no warranty, either expressed or implied, is provided in relation to
the accuracy or completeness of the information. The views expressed are our best judgment as of the date of issue and are subject to
change without notice. Prophecy Market Insights takes no responsibility for decisions made on the basis of these opinions.
 Any redistribution of this information is strictly prohibited. Copyright © 2019 Prophecy Market Insights pvt. Ltd , all rights reserved.
Legal and Copyright Notices
 While the editors endeavor to ensure the accuracy of all information and data contained in this Market Research Report, neither they
nor Prophecy Market Insights Pvt. Ltd. accept responsibility for any loss or damage (whether direct or indirect) whatsoever to the
customer or any third party resulting or arising there from.
 All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or
mechanical, including photocopying, recording, taping, or information storage and retrieval systems without permission of the
publisher.
Disclaimer:
Prophecy market Insights Pvt. Ltd attempts to ensure that the information provided in our market research reports is as accurate and
complete as possible, the quantity of detailed information used and the fact that some of the information (which cannot always be verified
or validated) is supplied by third parties and sources not controlled by prophecy market Insights Pvt. ltd means that we cannot always
guarantee the accuracy, completeness or originality of the information in some reports, and we are therefore not responsible for any errors
or omissions in those reports. The recipients of these reports are responsible for determining whether the information contained therein is
sufficient for use and shall use their own skill and judgement when choosing to rely upon the reports

Abbreviations
Abbreviation and Full Form
Abbreviation Full Form
HHS U.S. Department of Health & Human Services
PHAC Public Health Agency of Canada
NRC National Research Council
IVD Invitro Diagnostics
CLIA Clinical Laboratory Improvement Admendments
SME Small and Application-sized enterprises
IT Information Technology
CDC Centers for Disease Control and Prevention
COVID-19 Coronavirus Pandemic
RAD Rapid Acceleration of Diagnostics
NAA National Anti-profiteering Authority
U.S. United States
NA North America
KPI Key Performing Indicators

T H A N K
YOU
To know more about us, please visit our website:
www.prophecymarketinsights.com
For sales queries or new topics email us on:
sales@prophecymarketinsights.com
For other queries contact:
Abhijeet Mahajan
(Senior Associate Consultant)
Prophecy Market Insights
Email: abhijeet.m@prophecymarketinsights.com

P-o-c Molecular Diagnostic Market Trends, Analysis, and Forecast till 2034

Recommended

Recommended

More Related Content

Similar to P-o-c Molecular Diagnostic Market Trends, Analysis, and Forecast till 2034

Similar to P-o-c Molecular Diagnostic Market Trends, Analysis, and Forecast till 2034 (20)

Recently uploaded

Recently uploaded (20)

P-o-c Molecular Diagnostic Market Trends, Analysis, and Forecast till 2034